Add like
Add dislike
Add to saved papers

Citrullinated Aggrecan Epitopes as Targets of Auto-reactive CD4+ T cells in Patients with Rheumatoid Arthritis.

Arthritis & Rheumatology 2018 November 3
OBJECTIVE: Recognition of citrullinated antigens such as vimentin, fibrinogen, and alpha-enolase is associated with rheumatoid arthritis (RA). Emerging data suggests that the matrix protein aggrecan is also recognized as a citrullinated antigen. The goal of this study was to directly visualize cit-aggrecan specific T cells and characterize them in subjects with RA.

METHODS: Citrullinated aggrecan peptides with likely DRB1*04:01 binding motifs were predicted using a previously published scanning algorithm. Peptides with detectable binding were assessed for immunogenicity by HLA tetramer staining, followed by single cell cloning. Selectivity for citrullinated peptide was assessed through tetramer staining and proliferation assays. Ex vivo tetramer staining was then employed to assess frequencies of aggrecan specific T cells in peripheral blood. Finally, disease association was assessed by comparing T cell frequencies in RA patients and controls and correlating aggrecan specific T cells with levels of aggrecan specific antibodies.

RESULTS: We identified six immunogenic peptides, two of which were the predominant T cell targets in peripheral blood. These two epitopes were citrullinated at HLA binding residues and shared homologous sequences. RA patients had significantly higher frequencies of cit-aggrecan-specific T cells than healthy subjects. Furthermore, T cell frequencies were significantly correlated with antibodies against citrullinated aggrecan.

CONCLUSION: Our findings indicate that T cells that recognize citrullinated aggrecan are present in subjects with RA and correlate with antibodies that target this same antigen. Consequently, aggrecan-specific T cells and antibodies are potentially relevant markers that could be utilized to monitor patients with RA or at risk subjects. This article is protected by copyright. All rights reserved.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app